miRNA ½ÃÄö½º ¹× ¾î¼¼ÀÌ ½ÃÀå : Á¦Ç°¡¤¼­ºñ½º, ±â¼ú, ¿öÅ©Ç÷οì, ÃÖÁ¾»ç¿ëÀÚ, ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)
miRNA Sequencing & Assay Market by Product & Service (Products, Services), Technology (Nanopore Sequencing, Sanger Sequencing, Sequencing By Oligonucleotide Ligation & Detection), Workflow, End-User, Application - Global Forecast 2025-2030
»óǰÄÚµå : 1599693
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 183 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

miRNA ½ÃÄö½º & ¾î¼¼ÀÌ ½ÃÀåÀº 2023³â¿¡ 3¾ï 3,335¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 3¾ï 8,021¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 14.15%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 8¾ï 4,192¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿¬±¸ ¹æ¹ý·Ð miRNA ½ÃÀåÀº À¯ÀüÀÚ ¹ßÇöÀÇ Áß¿äÇÑ Á¶Àý ÀÎÀÚÀÎ ¸¶ÀÌÅ©·Î RNA¸¦ ºÐ¼®Çϱâ À§ÇØ ¼³°èµÈ ±¤¹üÀ§ÇÑ ±â¼ú°ú ¹æ¹ýÀ» ±¸Ã¼È­Çϰí ÀÖÀ¸¸ç, miRNA ½ÃÄö½ÌÀÇ Çʿ伺Àº ¾Ï, ½ÉÇ÷°ü Áúȯ, ½Å°æ ÅðÇ༺ Áúȯ°ú °°Àº Áúº´À» ÀÌÇØÇÏ´Â µ¥ ÀÖÀ¸¸ç, ÀáÀçÀûÀÎ ÀÀ¿ëÀ¸·Î ÀÎÇØ ¹ß»ýÇÑ´Ù, ¹ÙÀÌ¿À¸¶Ä¿ ¹ß±¼°ú ¸ÂÃãÀÇ·á¿¡ Å« Àü¸ÁÀ» °¡Á®´Ù ÁÙ °ÍÀÔ´Ï´Ù. ±× ÃÖÁ¾ ¿ëµµ´Â Çмú¿¬±¸ ±â°ü, Á¦¾à ȸ»ç, »ý¸í°øÇÐ ±â¾÷, ÷´Ü ¿¬±¸¿¡ Á¾»çÇÏ´Â ÀÓ»ó ¿¬±¸¼Ò¿¡ À̸£±â±îÁö ´Ù¾çÇÕ´Ï´Ù. ¼ºÀå ¿äÀÎÀ¸·Î´Â Á¤È®¼º°ú ºñ¿ë È¿À²¼ºÀ» ³ôÀÌ´Â ½ÃÄö½Ì ±â¼úÀÇ ¹ßÀü, Á¤¹Ð ÀÇÇп¡¼­ À¯ÀüüÇп¡ ´ëÇÑ °ü½É Áõ°¡, ¿¬±¸ ÀÚ±ÝÀÇ È®´ë µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. °¡Àå ÃÖ±Ù ÀáÀçÀû ±âȸ´Â ¾×ü»ý°ËÀ» ÅëÇØ Áúº´À» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀû Áø´Ü Åø¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÀÖ½À´Ï´Ù. ±â¾÷Àº ¿¬±¸±â°ü°úÀÇ ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ±â¼ú Çõ½ÅÀ» ºü¸£°Ô ÁøÇàÇϰí, RNA Ä¡·áÁ¦¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â °ÍÀ» Ȱ¿ëÇØ¾ß ÇÕ´Ï´Ù. ±×·¯³ª ½ÃÀåÀº ³ôÀº ½ÃÄö¼­ ¹× ºÐ¼® ºñ¿ë, µ¥ÀÌÅÍ ºÐ¼®ÀÇ º¹À⼺, ±ÔÁ¦ ¹®Á¦ µîÀÇ Á¦¾à¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¥ÀÌÅÍ ºÐ¼®ÀÇ ÆíÂ÷, Ç¥ÁØÈ­µÈ ÇÁ·ÎÅäÄÝÀÇ ºÎÀç µîÀÇ ¹®Á¦µµ ÇØ°áÇØ¾ß ÇÒ °úÁ¦ÀÔ´Ï´Ù. ±â¼ú Çõ½ÅÀ» À§ÇÑ °¡Àå ÁÁÀº ºÐ¾ß·Î´Â Àú·ÅÇÏ°í »ç¿ëÇϱ⠽¬¿î ½ÃÄö½Ì Ç÷§ÆûÀÇ °³¹ß, ´õ ³ªÀº ÇØ¼®À» À§ÇÑ AI ÅëÇÕÀ» ÅëÇÑ µ¥ÀÌÅÍ ºÐ¼® ÅøÀÇ °³¼±, miRNA ±â´É¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ µ¥ÀÌÅͺ£À̽ºÀÇ È®Àå µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ±ÔÁ¦±â°ü°úÀÇ Çù·ÂÀº Ç¥ÁØÀ» È®¸³Çϰí ÄÄÇöóÀ̾𽺠¹®Á¦¸¦ ÇØ°áÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀ̸ç, miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀåÀÇ Æ¯¼ºÀº ±â¼ú ¹ßÀü°ú Á¤¹ÐÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î ¿ªµ¿ÀûÀ¸·Î º¯È­Çϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ȯ°æÀ» ±Øº¹Çϰí, R& D¿¡ ÅõÀÚÇÏ¿© ºñ¿ëÀ» Àý°¨Çϰí, ´Ù¾çÇÑ Áúº´¿¡¼­ miRNAÀÇ ¿ªÇÒ¿¡ ´ëÇÑ ÀÌÇØ¸¦ ³ôÀÏ ¼ö ÀÖ´Â ±â¾÷Àº Àå±âÀûÀÎ ¼ºÀå°ú ¿µÇâ·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖ´Â À¯¸®ÇÑ À§Ä¡¿¡ ÀÖ½À´Ï´Ù. ±³À° ÇÁ·Î±×·¥¿¡ ÁýÁßÇÔÀ¸·Î½á ½ÃÀå È®´ë¿Í Çõ½ÅÀ» ´õ¿í ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023] 3¾ï 3,335¸¸ ´Þ·¯
¿¹Ãø³â[2024] 3¾ï 8,021¸¸ ´Þ·¯
¿¹Ãø³â[2030] 8¾ï 4,192¸¸ ´Þ·¯
CAGR(%) 14.15%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÕ´Ï´Ù.

miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­Çϰí, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Portre's Five Forces: miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« Åø

"Portre's Five Forces" ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÆÄ¾ÇÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ

miRNA ½ÃÄö½Ì ¹× ºÐ¼® ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ±â¾÷Àº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå miRNA ½ÃÄö½º & ¾î¼¼ÀÌ ½ÃÀå : Á¦Ç°¡¤¼­ºñ½ºº°

Á¦7Àå miRNA ½ÃÄö½º & ¾î¼¼ÀÌ ½ÃÀå : ±â¼úº°

Á¦8Àå miRNA ½ÃÄö½º & ¾î¼¼ÀÌ ½ÃÀå : ¿öÅ©Ç÷ο캰

Á¦9Àå miRNA ½ÃÄö½º & ¾î¼¼ÀÌ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå miRNA ½ÃÄö½º & ¾î¼¼ÀÌ ½ÃÀå : ¿ëµµº°

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ miRNA ½ÃÄö½º & ¾î¼¼ÀÌ ½ÃÀå

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ miRNA ½ÃÄö½º & ¾î¼¼ÀÌ ½ÃÀå

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ miRNA ½ÃÄö½º & ¾î¼¼ÀÌ ½ÃÀå

Á¦14Àå °æÀï ±¸µµ

±â¾÷ ¸®½ºÆ®

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The miRNA Sequencing & Assay Market was valued at USD 333.35 million in 2023, expected to reach USD 380.21 million in 2024, and is projected to grow at a CAGR of 14.15%, to USD 841.92 million by 2030.

The miRNA Sequencing & Assay market embodies the expansive scope of technologies and methodologies designed to analyze microRNAs, critical regulators of gene expression. The necessity of miRNA sequencing arises from its potential applications in understanding diseases, including cancer, cardiovascular, and neurodegenerative disorders, offering significant prospects for biomarker discovery and personalized medicine. Its end-use scope spans academic research institutions, pharmaceutical and biotechnological companies, and clinical laboratories engaged in cutting-edge research. Influencing growth factors include advancements in sequencing technologies that enhance accuracy and cost-effectiveness, a rising focus on genomics in precision medicine, and expanded research funding. Latest potential opportunities lie in the increasing demand for non-invasive diagnostic tools, enabling early disease detection through liquid biopsies. Companies should exploit partnerships with research institutes to fast-track innovation and capitalize on the rising interest in RNA therapeutics. However, the market faces limitations from the high cost of sequencers and assays, the complexity of data interpretation, and regulatory challenges. Additionally, variability in data analysis and a lack of standardized protocols present challenges that require resolution for more widespread adoption. The best areas for innovation include developing affordable and user-friendly sequencing platforms, improving data analytics tools with AI integration for better interpretation, and expanding comprehensive databases for miRNA function. Collaborations with regulatory agencies could aid in establishing standards and addressing compliance concerns. The nature of the miRNA Sequencing & Assay market is dynamic, driven by technological advancement and the escalating demand for precision healthcare solutions. Companies that can navigate regulatory landscapes, invest in R&D to reduce costs, and broaden the understanding of miRNA's role in various conditions are well-positioned to sustain long-term growth and impact. Enhanced focus on training programs to skill scientists in miRNA technologies and data analysis can further catalyze market expansion and innovation.

KEY MARKET STATISTICS
Base Year [2023] USD 333.35 million
Estimated Year [2024] USD 380.21 million
Forecast Year [2030] USD 841.92 million
CAGR (%) 14.15%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving miRNA Sequencing & Assay Market

The miRNA Sequencing & Assay Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the miRNA Sequencing & Assay Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the miRNA Sequencing & Assay Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the miRNA Sequencing & Assay Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the miRNA Sequencing & Assay Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the miRNA Sequencing & Assay Market

A detailed market share analysis in the miRNA Sequencing & Assay Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the miRNA Sequencing & Assay Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the miRNA Sequencing & Assay Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the miRNA Sequencing & Assay Market

A strategic analysis of the miRNA Sequencing & Assay Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the miRNA Sequencing & Assay Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Bio-Rad Laboratories, Inc., Global Life Sciences Solutions USA LLC, HTG Molecular Diagnostics, Inc., Illumina, Inc., Integrated DNA Technologies, Inc, Lexogen GmbH, Meridian Bioscience Inc, New England Biolabs (UK) Ltd., Norgen Biotek Corp., Oxford Nanopore Technologies Limited, Rosetta Genomics Ltd., Sigma Aldrich Corp., System Biosciences, LLC, Thermo Fisher Scientific Inc., and TriLink BioTechnologies, Inc..

Market Segmentation & Coverage

This research report categorizes the miRNA Sequencing & Assay Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. miRNA Sequencing & Assay Market, by Product & Service

7. miRNA Sequencing & Assay Market, by Technology

8. miRNA Sequencing & Assay Market, by Workflow

9. miRNA Sequencing & Assay Market, by End-User

10. miRNA Sequencing & Assay Market, by Application

11. Americas miRNA Sequencing & Assay Market

12. Asia-Pacific miRNA Sequencing & Assay Market

13. Europe, Middle East & Africa miRNA Sequencing & Assay Market

14. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â